In order to further unveil the possibility of lapatinib therapy in breast cancer chemoprevention, we investigated the effect of short-term lapatinib exposure during the premalignant risk window on the development of mammary tumors in MMTV-erbB-2 transgenic mice. This evidence concerns the gene ERBB2 and breast cancer.